1. Home
  2. GNPX vs SYNX Comparison

GNPX vs SYNX Comparison

Compare GNPX & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.01

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$1.12

Market Cap

7.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
SYNX
Founded
2009
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
7.1M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
GNPX
SYNX
Price
$2.01
$1.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
834.0K
3.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
76.33
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$32.35
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.73
52 Week High
$12.97
$4.39

Technical Indicators

Market Signals
Indicator
GNPX
SYNX
Relative Strength Index (RSI) 47.73 50.67
Support Level $1.88 $0.90
Resistance Level $2.51 $1.31
Average True Range (ATR) 0.13 0.17
MACD 0.02 -0.00
Stochastic Oscillator 58.93 19.49

Price Performance

Historical Comparison
GNPX
SYNX

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

Share on Social Networks: